Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04250337 · ClinicalTrials.gov registry record · Phase 3
Safety and Efficacy of Lebrikizumab (LY3650150) in Combination With Topical Corticosteroid in Moderate-to-Severe Atopic Dermatitis.
A Phase 3 study of Atopic Dermatitis, sponsored by Eli Lilly and Company.
- Completed
- Registry status
- Phase 3
- Development phase
- 228
- Enrollment target
- 20
- Study locations
NCT04250337 is a Phase 3 study of Atopic Dermatitis that has completed, run by Eli Lilly and Company. The registered enrollment target is 228 participants, below the 608-participant average among 150 other Atopic Dermatitis trials with a reported enrollment target (62% lower). The trial reports 20 study locations across 4 states.
The verdict
NCT04250337, a Phase 3 study of Atopic Dermatitis, has completed, sponsored by Eli Lilly and Company.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 228 participants
- Enrollment target
- 20
- Study locations
Study Summary
This is a randomized, double-blind, placebo-controlled, parallel-group study which is 16 weeks in duration. The study is designed to evaluate the safety and efficacy of lebrikizumab when used in combination with topical corticosteroid (TCS) treatment compared with placebo in combination with TCS treatment for moderate-to-severe atopic dermatitis.
Conditions Studied
Interventions
- OTHER Placebo
- BIOLOGICAL Lebrikizumab
- OTHER Topical Corticosteroid
Study Locations (20)
California
- Orange County Research Institute - Anaheim
- Bakersfield Dermatology and Skin Cancer Medical Group - Bakersfield
- Wallace Medical Group, Inc. - Beverly Hills
- First OC Dermatology - Fountain Valley
- Center For Dermatology Clinical Research, Inc. - Fremont
- California Allergy and Asthma Medical Group + Research Center - Los Angeles
- Keck School of Medicine University of Southern California - Los Angeles
- Dermatology Research Associates - Los Angeles
- LA Universal Research Center, INC - Los Angeles
- ACRC Studies - San Diego
- University Clinical Trials, Inc. - San Diego
- Southern California Dermatology, Inc. - Santa Ana
Florida
- St. Francis Medical Institute - Clearwater
- University of Florida - Gainesville - Gainesville
- Direct Helpers Medical Center - Hialeah
- The Community Research of South Florida - Hialeah
- GSI Clinical Research, LLC - Margate
- Vitae Research Center, LLC - Miami
Arizona
- Investigate MD - Scottsdale
District of Columbia
- Foxhall Dermatology - Washington D.C.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 228 participants |
| Start Date | 2020-02-03 |
| Est. Completion | 2021-09-16 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04250337
The ClinicalTrials.gov registry entry for NCT04250337 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 228 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 608-participant average among 150 other Atopic Dermatitis trials with a reported enrollment target (62% lower). The listed sponsor is Eli Lilly and Company, which has 1,341 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Atopic Dermatitis appearing as the primary indexed condition, and to 3 interventions - of which Placebo is the first listed.
NCT04250337 reports 20 study locations spanning 4 distinct geographic areas - top geographies include California, Florida, Arizona.
Frequently Asked Questions
What is clinical trial NCT04250337 about?
NCT04250337 is a clinical study titled "Safety and Efficacy of Lebrikizumab (LY3650150) in Combination With Topical Corticosteroid in Moderate-to-Severe Atopic Dermatitis.". This is a randomized, double-blind, placebo-controlled, parallel-group study which is 16 weeks in duration. The study is designed to evaluate the safety and efficacy of lebrikizumab when used in combination with topical corticosteroid (TCS) treatment compared with placebo in combination with TCS tre...
What is the current status of trial NCT04250337?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 228 participants. The study started on 2020-02-03. Estimated completion is 2021-09-16.
What conditions does trial NCT04250337 study?
This clinical trial studies the following conditions: Atopic Dermatitis.
What interventions are being tested in trial NCT04250337?
The interventions under investigation include: Placebo (OTHER), Lebrikizumab (BIOLOGICAL), Topical Corticosteroid (OTHER).
Who is sponsoring clinical trial NCT04250337?
This trial is sponsored by Eli Lilly and Company, which has 1,341 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04250337 being conducted?
This trial has 20 study locations across Arizona, California, District of Columbia, Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Atopic Dermatitis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study to Investigate Safety and Efficacy of Tapinarof Cream, 1% in Participants Ages 3 Months to < 24 Months With Atopic Dermatitis
RECRUITING · Phase 3
-
A Long-term Study of the Medicine Called Abrocitinib in Children Aged 2 Years and Older With Moderate to Severe Eczema
RECRUITING · Phase 3
-
A Trial to Evaluate the Efficacy and Safety of Tralokinumab in Combination With Topical Corticosteroids in Children and Infants With Moderate-to-severe Atopic Dermatitis
RECRUITING · Phase 3
-
A Study to Assess Adverse Events and Change in Disease Activity Comparing Oral Upadacitinib to Subcutaneous Dupilumab in Children From 2 to Less Than 12 Years of Age With Moderate to Severe Atopic Dermatitis
RECRUITING · Phase 3
-
A Study to Assess the Efficacy and Safety of Ruxolitinib Cream in Children and Adolescents (6 to <18 Years Old) With Moderate Atopic Dermatitis
RECRUITING · Phase 3
-
A Study of Upadacitinib in Adult Participants With Moderate-to-Severe Atopic Dermatitis and Inadequate Response to Dupilumab
RECRUITING · Phase 3
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.